{"news": [{"date": "20240405155020", "headline": "Astrazeneca (AZN) Advances But Underperforms Market: Key Facts", "summary": "Astrazeneca (AZN) closed the most recent trading day at $67.45, moving +0.16% from the previous trading session."}, {"date": "20240405174014", "headline": "15 Most Densely Populated Cities in Europe", "summary": "In this article, we will be looking at the 15 most densely populated cities in Europe. If you wish to skip our detailed analysis, you can go directly to the 5 Most Densely Populated Cities in Europe. Europe\u2019s Population in the Broader Context of World Population Spread over a total area of 22,134,900 sq. km, [\u2026]"}, {"date": "20240405194300", "headline": "ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors", "summary": "WILMINGTON, Del., April 06, 2024--AstraZeneca and Daiichi Sankyo's ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options."}, {"date": "20240405211000", "headline": "ENHERTU\u00ae Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors", "summary": "TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU\u00ae Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors"}, {"date": "20240406004500", "headline": "ClearBridge Dividend Strategy Q1 2024 Portfolio Manager Commentary", "summary": "The market\u00e2\u0080\u0099s rise continues to be led by a small handful of mega cap technology names, with those companies and the IT sector together now accounting for almost 40% of the S&P 500 Index."}, {"date": "20240406020506", "headline": "Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca PLC (LON:AZN)", "summary": "Key Insights AstraZeneca to hold its Annual General Meeting on 11th of April Total pay for CEO Pascal Soriot includes..."}, {"date": "20240406184753", "headline": "10 Best Weight Loss Drug Stocks to Buy Now", "summary": "In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it\u2019s one of the biggest trends on the stock market right now, then you can take a look at the [\u2026]"}, {"date": "20240406230500", "headline": "ENHERTU approved for treatment of unresectable or metastatic HER2 positive", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240406230800", "headline": "US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407195300", "headline": "TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407204300", "headline": "LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407213600", "headline": "TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240407235900", "headline": "AstraZeneca\u2019s Enhertu Wins US Approval for Tumours", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240408014200", "headline": "Nuvectis says NXP900 demonstrates robust activity in NSCLC", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240408072100", "headline": "AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors", "summary": "FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies."}, {"date": "20240408103433", "headline": "AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor", "summary": "On Friday, the FDA approved Daiichi Sankyo Ltd\u2019s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc\u2019s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indicat"}, {"date": "20240408195800", "headline": "The top 10 names with relative cheap earnings volume for the season - Barclays", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240408230000", "headline": "UK pharma companies told to make fewer drugs in draft Treasury net zero guidelines", "summary": "Pharmaceuticals companies were told to make fewer drugs for the sake of the environment, in new draft guidelines for businesses in the Government\u2019s latest net zero drive."}, {"date": "20240409015700", "headline": "Vincerx in selloff after early-stage data for cancer therapy", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409051800", "headline": "Global company events calendar", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409052000", "headline": "UK shareholder meetings calendar - next 21 days", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409055900", "headline": "JPMorgan\u2019s top European picks", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409193600", "headline": "AstraZeneca\u2019s Enhertu Approval Spurs Buy Rating Amid Revenue Growth Projections", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409220045", "headline": "ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?", "summary": "Despite the market\u2019s hot year-to-date run, there\u2019s no shortage of affordable stocks that also have impressive growth profiles. In the biotech scene, numerous firms can harness a technological edge to improve various aspects of health and medicine. From genetic medicine to less-invasive disease diagnostics, this piece will check out three Strong-Buy-rated stocks\u2014ZTS, EXAS, and AZN\u2014that I view as among the most investable in the often-choppy biopharmaceutical scene. Though individual biotech and b"}, {"date": "20240409222400", "headline": "Roche announces CE Mark for Ventana HER2 Rabbit Monoclonal Primary RxDx", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409225000", "headline": "Roche companion diagnostic test wins CE Mark to identify metastatic breast cancer patients", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410001100", "headline": "Analysts\u2019 Top Healthcare Picks: AstraZeneca (AZN), Centessa Pharmaceuticals (CNTA)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410040900", "headline": "UK shareholder meetings calendar - next 7 days", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410041027", "headline": "Major investors say AstraZeneca boss is \u2018massively underpaid\u2019 on $21.5 million salary, despite earning more than double Novo Nordisk\u2019s CEO", "summary": "Shareholder advisors are urging investors to vote against Pascal Soriot's proposed $2.3 million raise, arguing it is excessive."}, {"date": "20240410065000", "headline": "ClearBridge Value Equity Strategy Q1 2024 Portfolio Manager Commentary", "summary": "The ClearBridge Value Equity Strategy outperformed its Russell 1000 Value Index during the first quarter of 2024. Click here to read the full fund letter."}, {"date": "20240410183000", "headline": "GLOBAL BRIEFING: Chinese inflation cooler than expected in March", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410192800", "headline": "AstraZeneca\u2019s AGM: Resolutions Passed with Support", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410204900", "headline": "LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410212400", "headline": "What You Missed On Wall Street On Thursday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410215400", "headline": "LONDON MARKET OPEN: European markets mixed ahead of ECB decision", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410215600", "headline": "TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410222300", "headline": "AstraZeneca to boost annual dividend by 7%", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410231500", "headline": "AstraZeneca increases 2024 dividend by 7% to $3.10 per share", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411000600", "headline": "AstraZeneca announces FDA approval for Fasenra", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411002700", "headline": "AstraZeneca Confirms Dividend Hike for 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411003029", "headline": "AstraZeneca announces dividend hike ahead of CEO pay vote", "summary": "(Reuters) -Drugmaker AstraZeneca plans to raise its annual dividend by 7% for 2024, it said on Thursday, ahead of a shareholder vote on a hefty boost to its Chief Executive's pay package.  Shareholders, meanwhile, are preparing to vote at the annual general meeting on a policy that could raise CEO Pascal Soriot's pay package by 1.8 million pounds ($2.26 million) to a maximum of 18.9 million pounds in 2024.  Influential proxy advisers Glass Lewis and ISS have urged shareholders to vote against the policy, according to reports."}, {"date": "20240411005000", "headline": "LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411020822", "headline": "AstraZeneca promises dividend rise ahead of vote on chief\u2019s \u00a318.7m pay deal", "summary": "The update came ahead of AstraZeneca\u2019s annual general meeting on Thursday afternoon."}, {"date": "20240411031654", "headline": "CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision", "summary": "European shares slipped on Thursday as investors avoided big bets ahead of a monetary policy decision by the European Central Bank and remarks by ECB's Christine Lagarde on the outlook for interest rate cuts.  The pan-European STOXX 600 lost 0.3%, as of 0906 GMT."}, {"date": "20240411043640", "headline": "Trending tickers: Darktrace, AstraZeneca, Persimmon, Bitcoin", "summary": "The latest investor updates on stocks that are trending on Thursday."}, {"date": "20240411050000", "headline": "FASENRA approved for treatment of children aged 6 to 11 with severe asthma", "summary": "WILMINGTON, Del., April 11, 2024--AstraZeneca\u2019s FASENRA\u00ae (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1"}, {"date": "20240411050300", "headline": "What You Missed On Wall Street This Morning", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411055300", "headline": "LONDON MARKET CLOSE: Dwindling US Fed cut hope unnerves markets", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411105319", "headline": "UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition", "summary": "AstraZeneca shareholders on Thursday approved a 2024 pay policy which will boost CEO Pascal Soriot's remuneration to as much as 18.9 million pounds ($23.7 million) this year, but over a third of investors revolted against the huge sum.  High executive pay in Britain has long been contentious, particularly with pay for ordinary workers rising far more slowly, and Soriot's pay package has proved a lightning rod for investor discontent in the past.  In 2021 \u2014 the last time AstraZeneca's long-term incentives policy was reviewed \u2014 almost 40% of votes were cast against it, and proxy advisory groups Glass Lewis and ISS also opposed the plan, as they did this year."}, {"date": "20240411110137", "headline": "AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition", "summary": "High executive pay in Britain has long been contentious, particularly with pay for ordinary workers rising far more slowly, and Soriot's pay package has proved a lightning rod for investor discontent in the past.  In 2021 \u2014 the last time AstraZeneca's long-term incentives policy was reviewed \u2014 almost 40% of votes were cast against it, and proxy advisory groups Glass Lewis and ISS also opposed the plan, as they did this year.  Despite the notable no votes, the final result is a major boost to one of the best-paid executives among London's blue-chip FTSE 100 at a time when British firms are looking to match U.S. and European rivals' pay packages."}, {"date": "20240411113203", "headline": "World risks \u2018tepid Twenties\u2019 as debt levels and inflation soar, warns IMF", "summary": "The world is at risk of a \u201csluggish and disappointing decade\u201d, the head of the International Monetary Fund has warned, while urging vigilance to restore price stability and jumpstart economic growth."}, {"date": "20240411115335", "headline": "AstraZeneca hit by investor backlash over chief Pascal Soriot\u2019s \u00a319m pay deal", "summary": "AstraZeneca has suffered an investor backlash over a \u00a319m pay award for its chief executive, in a vote that will deepen concerns of an exodus of UK companies to the US."}, {"date": "20240411161516", "headline": "Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know", "summary": "Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session."}, {"date": "20240412000900", "headline": "No link between weight loss drugs and suicidal thoughts, EU regulator concludes", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412020100", "headline": "Biogen Is Suffering From Doubts About the Future", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412034400", "headline": "Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412072200", "headline": "Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News", "summary": "J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors."}, {"date": "20240412073000", "headline": "U.K. Top 40 Quality Dividend Stocks: Q2 2024", "summary": "The list ranks quality dividend stocks with long track records of progressive dividend growth. Read what investors need to know."}, {"date": "20240412083300", "headline": "AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids", "summary": "The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years."}, {"date": "20240414024100", "headline": "4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market", "summary": "Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights."}, {"date": "20240415005800", "headline": "GLOBAL BROKER RATINGS: Morgan Stanley raises Adidas; BofA cuts ABB", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415155131", "headline": "3 Pharma Stocks That Are Money-Printing Machines in 2024", "summary": "The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy\u2019s resilience. The well established pharmaceutical industry continues to assert its economic dominance through resolute financials. In 2022, pharma stocks brought in $510.5 billion, with forecasts for the sector to reach $863.6 billion in revenue by 2030. Between 2023 and 2030, the industry"}, {"date": "20240415213900", "headline": "AstraZeneca's hails Imfinzi survival data on cancer form", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415224800", "headline": "LONDON BROKER RATINGS: RBC raises Admiral; Barclays cuts Phoenix Group", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415231400", "headline": "J.P. Morgan outlines major European players flagging pricing power issues in earnings", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415232100", "headline": "AstraZeneca reports updated exploratory results from TOPAZ-1 Phase 3 trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416001200", "headline": "AstraZeneca: Imfinzi + chemo doubled OS at  three years for patients with BTC", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416003800", "headline": "IN THE KNOW: Deutsche ups AstraZeneca as higher payout addresses worry", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416012100", "headline": "GLOBAL BROKER RATINGS: Deutsche Bank lifts AstraZeneca, cuts Honeywell", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416013900", "headline": "AstraZeneca Imfinzi long-term survival buoyed by new data", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416015700", "headline": "AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416020000", "headline": "Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416050000", "headline": "IMFINZI\u00ae (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial", "summary": "WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca\u2019s IMFINZI\u00ae (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC)."}, {"date": "20240416055000", "headline": "AstraZeneca upgraded to Hold from Sell at Deutsche Bank (earlier)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416081655", "headline": "VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'", "summary": ""}, {"date": "20240416194100", "headline": "Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417065500", "headline": "International Wide-Moat Stocks On Sale - The April 2024 Heat Map", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418024100", "headline": "Unusually active option classes on open April 18th", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418094503", "headline": "Astrazeneca (AZN) Could Be a Great Choice", "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out."}, {"date": "20240418195100", "headline": "Tech advances are catalyzing the Health Care sector with improved investor sentiment - SSGA", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418214800", "headline": "Looking At AstraZeneca's Recent Unusual Options Activity", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418231500", "headline": "3 Blue-Chip Stocks to Buy as High Inflation Persists", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419044300", "headline": "Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419120522", "headline": "20 Countries with the Highest Cancer Survival Rates in the World", "summary": "In this article, we will be taking a look at the 20 countries with the highest cancer survival rates in the world. If you do not want to learn about the cancer treatment in the US, head straight to the 5 Countries with the Highest Cancer Survival Rates in the World. Navigating the Terrain: The [\u2026]"}, {"date": "20240420013100", "headline": "Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240420224900", "headline": "Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421010500", "headline": "Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240421083958", "headline": "11 Best Low Price Pharma Stocks To Invest In", "summary": "In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma [\u2026]"}, {"date": "20240422010000", "headline": "European Stock: AstraZeneca", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422034500", "headline": "UK earnings, trading statements calendar - next 21 days", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422034500", "headline": "UK earnings, trading statements calendar - next 7 days", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422071609", "headline": "Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics", "summary": "Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024."}, {"date": "20240422072746", "headline": "With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing", "summary": "Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their..."}, {"date": "20240422200300", "headline": "3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422223200", "headline": "AstraZeneca PLC ADR rises Tuesday, still underperforms market", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422233100", "headline": "AstraZeneca reports Voydeya approved in EU as PNH add-on treatment", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423020100", "headline": "Takeda Pharmaceutical: A Long-Term Cash Cow", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423033000", "headline": "Baron Health Care Fund Q1 2024 Shareholder Letter", "summary": "In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared with the 8.52% gain for the Russell 3000 Health Care Index and the 10.56% gain for the S&P 500 Index."}, {"date": "20240423075800", "headline": "AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect", "summary": "Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications."}, {"date": "20240423201900", "headline": "Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423223040", "headline": "AstraZeneca: What The Market's Missing", "summary": "AstraZeneca has a strong pipeline, recent approvals, and a series of acquisitions that offer promising prospects. Read why AZN stock is a Buy."}, {"date": "20240423231000", "headline": "AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423233200", "headline": "Angle shares jump on supplier agreement with with AstraZeneca", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424041700", "headline": "Notable earnings before Thursday's open", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424052700", "headline": "AstraZeneca Q1 2024 Earnings Preview", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424060000", "headline": "LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424060600", "headline": "CORRECT: No record close for FTSE 100; mixed trade in US", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424155048", "headline": "Alphabet, Microsoft, Southwest earnings: What to watch", "summary": "Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith"}, {"date": "20240424193000", "headline": "AstraZeneca beats top-line and bottom-line estimates; reaffirms FY24 outlook", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424193700", "headline": "GET READY: AstraZeneca, Barclays, J Sainsbury, Relx, Weir at 0700 BST", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424201700", "headline": "AstraZeneca Sees Strong Growth in Q1 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424221200", "headline": "LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424221800", "headline": "TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424223900", "headline": "AZN Earnings: AstraZeneca Soars on Impressive Q1 Results", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424225000", "headline": "AstraZeneca reports Q1 core EPS $2.06, consensus $1.22", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424225200", "headline": "AstraZeneca backs FY24 core EPS view up low double-digit to low teens percentage", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424225700", "headline": "Biggest stock movers today: META, IBM, F, and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424230900", "headline": "Astrazeneca: Q1 Earnings Snapshot", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424232300", "headline": "US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425000000", "headline": "Q1 2024 results", "summary": "CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)"}, {"date": "20240425000619", "headline": "AstraZeneca trounces first-quarter estimates as resilient demand fuels growth", "summary": "CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes.  Combined revenue from partnered medicines, such as breast cancer therapy Enhertu with Daiichi Sankyo and asthma medicine Tezspire with Amgen, jumped by more than 60% in the three-month period, fuelling overall growth.  The number two London-listed company by market value reported core earnings per share of $2.06 on a 19% year-on-year rise in total revenue to $12.68 billion."}, {"date": "20240425001059", "headline": "UPDATE 2-AstraZeneca trounces first-quarter estimates as resilient demand fuels growth", "summary": "AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, underpinning strong demand for its blockbuster drugs and steady sales from partnered medicines.  Oncology, the Anglo-Swedish drugmaker's top business, clocked a 26% jump in first-quarter sales to $5.12 billion.  CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes."}, {"date": "20240425002800", "headline": "AstraZeneca\u2019s Q1 2024: Revenue and Dividend Leap", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425005000", "headline": "LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425005600", "headline": "AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425014300", "headline": "AstraZeneca rises as oncology business drives Q1 beat", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425030900", "headline": "Biggest stock movers today: LUV, META, IBM, F, and more", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425032200", "headline": "Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425032900", "headline": "AstraZeneca Earnings, Sales Rise, Beat Forecasts", "summary": "AstraZeneca reiterated its full-year guidance after posting first-quarter core earnings and sales above forecasts."}, {"date": "20240425035651", "headline": "Trending tickers: Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's", "summary": "The latest investor updates on stocks that are trending on Thursday."}, {"date": "20240425041800", "headline": "What's Driving AstraZeneca PLC's Surprising 14% Stock Rally?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425060000", "headline": "AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting", "summary": "AbelZeta Pharma, Inc. (\"AbelZeta\" or the \"Company\"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M"}, {"date": "20240425063800", "headline": "Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425063840", "headline": "Cancer drugs help drive AstraZeneca sales sharply higher", "summary": "Shares in the Cambridge-based company jumped by 5% in early trading."}, {"date": "20240425073038", "headline": "Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say", "summary": "While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values."}, {"date": "20240425081900", "headline": "AstraZeneca\u2019s earnings surprise investors as cancer drugs fuel growth", "summary": "The British drugmaker has bolstered its business with nearly $5\u00a0billion in acquisitions as attention turns to its pipeline of experimental medicines."}, {"date": "20240425083033", "headline": "AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge", "summary": "AstraZeneca stock bolted higher Thursday \u2014 and is now within striking distance of a breakout \u2014 after its cancer drugs propelled a sales beat."}, {"date": "20240425090320", "headline": "AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance", "summary": "Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion. This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines. The company\u2019s adjusted EPADS reached $1.03, missing the consensus of $1.22. Also Read: AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO\u2019s Pay Package Boost. R&D expenses rose a"}, {"date": "20240425091900", "headline": "Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up", "summary": "Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year."}, {"date": "20240425093424", "headline": "20 Fastest Growing Health Tech Companies in the World", "summary": "In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital [\u2026]"}, {"date": "20240425093439", "headline": "AstraZeneca reinforcing supply chain amid global tensions: CEO", "summary": "AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its full-year guidance by claiming its \"core EPS is expected to increase by a low double-digit to low teens percentage.\" To keep that guidance, the company bolstered its drug production, particularly in China, as uncertainty caused by geopolitical conflicts gave cause for concern. Shares of the pharmaceutical giant are rising on this news. AstraZeneca CEO Pascal Soriot joins Yahoo Finance Health Reporter Anjalee Khemlani to discuss AstraZeneca's performance, its production abilities, and future cancer treatments. \"We are very much engaged in China, and we have been for many, many years. Having said that, of course, we have considered all this geopolitical tensions, and we have established a very resilient supply chain. We have manufacturing sites in China for China and some other countries in the emerging markets, in particular,\" Soriot speaks on the company's international ties. \"Aand of course, we have a supply chain that is dedicated to what you might call the Western world \u2014 the US and Europe, for instance. We are right now in the process of building a cell therapy manufacturing site in Maryland. So, we really have a very resilient supply chain that has shown that it can sustain a crisis, and the COVID was a good example of this. \" For more expert insight and the latest market action, click here to watch this full episode. This post was written by Nicholas Jacobino"}, {"date": "20240425103013", "headline": "AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript", "summary": "AZN earnings call for the period ending March 31, 2024."}, {"date": "20240425103619", "headline": "Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings;  AstraZeneca Shares See Post-Earnings Bump", "summary": "Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump"}, {"date": "20240425114700", "headline": "AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up", "summary": "AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs."}, {"date": "20240425134904", "headline": "AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'", "summary": "AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today."}, {"date": "20240425222800", "headline": "3 Best Healthcare Stocks to Buy in April 2024, According to Analysts", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425223300", "headline": "LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426002100", "headline": "Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and BioMarin Pharmaceutical (BMRN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426011500", "headline": "Top 4 Health Care Stocks That May Plunge This Month", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426013300", "headline": "GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426043800", "headline": "AstraZeneca price target raised by 500 GBp at Barclays", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426045900", "headline": "AstraZeneca price target raised by 600 GBp at UBS", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426053356", "headline": "AstraZeneca: Strong In A Weak Market", "summary": "Shares of AstraZeneca reached new all-time highs this week despite difficult market conditions in the last two months. Learn more on AZN stock here."}, {"date": "20240426072300", "headline": "Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect", "summary": "Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release."}, {"date": "20240426093400", "headline": "Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates", "summary": "Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results."}, {"date": "20240426204100", "headline": "Amgen\u2019s Blincyto data send Cullinan higher", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240427011643", "headline": "AstraZeneca PLC (LON:AZN) Beat Earnings, And Analysts Have Been Reviewing Their Forecasts", "summary": "As you might know, AstraZeneca PLC ( LON:AZN ) just kicked off its latest quarterly results with some very strong..."}, {"date": "20240427013000", "headline": "AstraZeneca: A Triple Shot Of Income, Growth, And Value", "summary": "AstraZeneca's impressive performance, solid financials, and potential for growth make it a compelling investment option with double-digit returns. Read more here."}, {"date": "20240427210000", "headline": "Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428060400", "headline": "J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428195400", "headline": "AstraZeneca\u2019s New Breast Cancer Treatment Nears EU Approval", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428200000", "headline": "ENHERTU\u00ae Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428200400", "headline": "AstraZeneca\u2019s Enhertu Shows Promise in Breast Cancer Trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428205000", "headline": "LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428221300", "headline": "AstraZeneca makes progress with Truqap and Enhertu cancer treatments", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428230200", "headline": "LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428232000", "headline": "AstraZeneca reports Truqap plus Faslodex recommended for EU approval by CHMP", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428233200", "headline": "AstraZeneca reports results from DESTINY-Breast06 Phase 3 trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429001000", "headline": "AstraZeneca and  Daiichi Sankyo's ENHERTU improves PFS in HER2-low", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429013300", "headline": "AstraZeneca's Enhertu buoyed by progression-free survival data in breast cancer", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429015900", "headline": "AIM ImmunoTech announces evaluation of first dose level in Phase 1b/2 study", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429022800", "headline": "GLOBAL BROKER RATINGS: Bernstein raises Apple, Barclays cuts JD Sports", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429022800", "headline": "AstraZeneca\u2019s Truqap Set for EU Approval", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429022900", "headline": "AstraZeneca\u2019s Enhertu Shows Breast Cancer Breakthrough", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429023000", "headline": "Double Good News For AstraZeneca's Breast Cancer Drugs", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429050000", "headline": "ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow", "summary": "WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU\u00ae (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy."}, {"date": "20240429051000", "headline": "AstraZeneca, Daiichi look to broaden Enhertu use again with new study data", "summary": "The drug benefited people whose tumors have \u201cultralow\u201d levels of HER2 protein, a result that could extend its reach in HER2-positive breast cancer."}, {"date": "20240429065600", "headline": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429082617", "headline": "AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement", "summary": "AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement"}, {"date": "20240429092224", "headline": "AstraZeneca\u2019s Fasenra: Approval for asthma may initiate COPD approval", "summary": "Therapies for COPD have been in development for decades to reduce exacerbations and manage the symptom load of the disease."}, {"date": "20240429143845", "headline": "AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown", "summary": "European pharma giant AstraZeneca Plc\u2019s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in numerous cases. Lawyers representing the plaintiffs argue that the vaccine resulted in side effects for a small number of families, including brain injuries and fatalities. AstraZeneca, while contesting the claims, has acknowledged in court documents that its vaccine can, in rare instances, cause Thro"}, {"date": "20240429192200", "headline": "Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430025300", "headline": "J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430031400", "headline": "FTC expands patent listing challenges for drugs", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430052400", "headline": "Novo, Teva, AstraZeneca issued FTC warnings over \u2018bogus\u2019 patents", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430070300", "headline": "US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240430084010", "headline": "AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript", "summary": "AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn\u2019t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining [\u2026]"}, {"date": "20240430211300", "headline": "Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501020100", "headline": "Novartis Is Tracking Well Above the Industry", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501050300", "headline": "AstraZeneca Shares Voting Rights Update", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501050500", "headline": "AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio", "summary": "WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as"}, {"date": "20240501061500", "headline": "AstraZeneca put volume heavy and directionally bearish", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501084105", "headline": "Eli Lilly Shoots Higher: It's Time To Be Cautious", "summary": "If we see shares continue to climb like this, a downgrade for Eli Lilly and Company stock could be on the horizon. Learn why we rate LLY stock a hold."}, {"date": "20240501100227", "headline": "AstraZeneca admits Covid-19 vaccine may cause blood clots in \u201cvery rare\u201d cases", "summary": "AstraZeneca has maintained that while the vaccine may, in \u201cvery rare\u201d cases, cause TTS, the casual mechanism for this effect remains unknown."}, {"date": "20240501191800", "headline": "AstraZeneca: Strong Q1 Earnings and Promising Pipeline Reinforce Buy Rating", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501193700", "headline": "Radiopharma stocks higher as sector welcomes the latest M&A deal", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501195500", "headline": "AstraZeneca\u2019s Calquence Sets New Standard in Lymphoma Care", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501230400", "headline": "AstraZeneca notes positive trial results for Calquence treatment", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501232200", "headline": "AstraZeneca announces results from interim analysis of ECHO Phase III trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502003200", "headline": "AstraZeneca\u2019s Calquence Shows Promise in Lymphoma Trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502050000", "headline": "CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial", "summary": "WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca\u2019s CALQUENCE\u00ae (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL)."}, {"date": "20240502064100", "headline": "10 Health Care Stocks Whale Activity In Today's Session", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502205000", "headline": "LONDON BRIEFING: InterContinental Hotels makes first-quarter progress", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502214800", "headline": "LONDON MARKET OPEN: Confident start before US jobs data", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502235200", "headline": "AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503005000", "headline": "Angle shares up on assay development deal with AstraZenaca", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503011700", "headline": "CORRECT: Angle shares up on assay development deal with AstraZeneca", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503022144", "headline": "AstraZeneca reports positive interim data from mantle cell lymphoma trial", "summary": "Calquence with chemoimmunotherapy improved progression-free survival in priorly untreated MCL patients."}, {"date": "20240503033700", "headline": "Amgen stock rallies 13% on GLP-1 weight-loss drug update", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503094800", "headline": "Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update", "summary": "Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is \"very encouraged\" by interim data from the phase II study on obesity candidate MariTide."}, {"date": "20240503095300", "headline": "Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx", "summary": "Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), QUALCOMM Incorporated (QCOM) and FedEx Corporation (FDX)."}]}